Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genzyme Sales Of Myozyme Doubled In Fourth Quarter 2007

This article was originally published in The Pink Sheet Daily

Executive Summary

Enzyme replacement therapy for Pompe disease recorded $62 million in sales in the quarter, representing the most rapid growth of any of the firm’s lysosomal products.

You may also be interested in...



Pending Approvals Hold Major Implications For Myozyme Growth

Genzyme reports increasing sales for Pompe disease drug, but upcoming EU and FDA decisions could spur or stifle product’s growth.

Pending Approvals Hold Major Implications For Myozyme Growth

Genzyme reports increasing sales for Pompe disease drug, but upcoming EU and FDA decisions could spur or stifle product’s growth.

Icahn Leaves Pool, Genzyme Shareholder No More

Cambridge neighbor Biogen Idec, meanwhile, girds for a power struggle at its May annual meeting.

Related Content

Topics

UsernamePublicRestriction

Register

ID005817

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel